You are here

  • Home
  • Archive
  • Volume 8, Issue 11
  • Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study)

Responses

Article menu

Download PDFPDF

Neurology
Protocol
Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation: protocol for a multicentre, prospective, observational, longitudinal cohort study (Strawberry study)
Compose a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on: 6 May 2020
    RE: Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation

    Saji et al. intended a prospective study to know the effects of warfarin therapy and direct oral anticoagulants (DOACs) on cerebrovascular diseases and cognitive impairment (CI) in patients with non-valvular atrial fibrillation (NVAF) over an estimated duration of 36 months (1). I want to present some information.

    First, Mongkhon et al. investigated the risk of dementia/CI among newly diagnosed atrial fibrillation (AF) patients with and without oral anticoagulation (OAC) treatment over a mean follow-up of 5.9 years (2). Hazard ratios (HRs) (95% confidence intervals [CIs) of OAC treatment and antiplatelets for dementia/CI were 0.90 (0.85-0.95) and 0.84 (0.79-0.90), respectively. In contrast, HR (95% CI) of DOACs treatment against warfarin for dementia/CI was 0.89 (0.70-1.14). Furthermore, HR (95% CI) of dual therapy (OAC plus antiplatelets) for dementia/CI was 1.17 (1.05-1.31). Saji et al. set two clinical outcomes, and study period was shorter. In addition, safety evaluation on bleeding might also be required.

    Second, Diener et al. recommended randomized trials to evaluate whether OAC, including warfarin and DOACs, reduces dementia/CI in AF patients (3). Dementia/CI, including vascular dementia and Alzheimer's disease, might be related to ischemic stroke, cerebral micro-infarcts, cerebral hemorrhage, and reduced cerebral blood flow. Taken together, risk assessment of medications for dementia/CI in AF patients would be closely associated with types of cer...

    Show More
    Conflict of Interest:
    None declared.
  • Published on: 27 April 2020
    RE: Protective effects of oral anticoagulants on cerebrovascular diseases and cognitive impairment in patients with atrial fibrillation

    Saji et al. intended a prospective study to know the effects of warfarin therapy and direct oral anticoagulants (DOACs) on cerebrovascular diseases and cognitive impairment (CI) in patients with non-valvular atrial fibrillation (NVAF) over an estimated duration of 36 months (1). I want to present some information.

    First, Mongkhon et al. investigated the risk of dementia/CI among newly diagnosed atrial fibrillation (AF) patients with and without oral anticoagulation (OAC) treatment over a mean follow-up of 5.9 years (2). Hazard ratios (HRs) (95% confidence intervals [CIs) of OAC treatment and antiplatelets for dementia/CI were 0.90 (0.85-0.95) and 0.84 (0.79-0.90), respectively. In contrast, HR (95% CI) of DOACs treatment against warfarin for dementia/CI was 0.89 (0.70-1.14). Furthermore, HR (95% CI) of dual therapy (OAC plus antiplatelets) for dementia/CI was 1.17 (1.05-1.31). Saji et al. set two clinical outcomes, and study period was shorter. In addition, safety evaluation on bleeding might also be required.

    Second, Diener et al. recommended randomized trials to evaluate whether OAC, including warfarin and DOACs, reduces dementia/CI in AF patients (3). Dementia/CI, including vascular dementia and Alzheimer's disease, might be related to ischemic stroke, cerebral micro-infarcts, cerebral hemorrhage, and reduced cerebral blood flow. Taken together, risk assessment of medications for dementia/CI in AF patients would be closely associated with types of cer...

    Show More
    Conflict of Interest:
    None declared.